General

What does Innocore do?

Innocore is a specialist drug delivery company focused on the development of long-acting injectable (LAI) formulations for peptides, biologics, oligonucleotides, and selected small molecules. We combine proprietary biodegradable polymer technologies, deep formulation expertise, and integrated development capabilities to create sustained-release injectable drug products with customized pharmacokinetic profiles.

What therapeutic areas does Innocore focus on?

Our technologies are broadly applicable across therapeutic areas such as site specific and or chronic disease. We currently see particularly strong interest in endocrinology (e.g. obese, diabetic, hormone), cardiometabolic disease, immunology, inflammation, ophthalmology, neurology, oncology, infectious diseases, and veterinary medicine.

What makes Innocore different from other LAI companies?

Innocore combines over 20 years of experience in biodegradable polymer science with proprietary SynBiosys® polymer technology platforms specifically designed to address the challenges associated with peptides and biologics. Our technologies enable tunable release kinetics while preserving API integrity and allowing scalable manufacturing.

Where is Innocore located?

Innocore is headquartered in Groningen, The Netherlands, where we operate state-of-the-art laboratories for polymer synthesis, formulation development, analytical characterization, and process development.

SynBiosys® Technology

What is SynBiosys®?

SynBiosys® is Innocore’s proprietary biodegradable polymer platform for long-acting injectable drug delivery. The platform enables the development of highly customizable sustained-release formulations with release durations ranging from weeks to months and supports multiple dosage forms, including microspheres, implants, and in situ forming depots.

Which drug modalities can be formulated using SynBiosys®?

SynBiosys® has been designed specifically for challenging APIs, including:

  • Peptides
  • Proteins and biologics
  • Antibodies and antibody fragments
  • Oligonucleotides
  • Small molecules
  • Emerging therapeutic modalities

What are the advantages of SynBiosys® compared with conventional PLGA systems?

Compared with traditional PLGA-based systems, SynBiosys® can offer:

  • Reduced risk of API degradation and acylation
  • Enhanced stabilization of sensitive biomolecules
  • Highly tunable release profiles
  • Greater flexibility in formulation design
  • Multiple dosage form options
  • Simplified scale-up and manufacturing transfer

Is SynBiosys® clinically validated?

Yes. SynBiosys® polymers have demonstrated safety and efficacy in multiple preclinical and clinical programs, and products incorporating SynBiosys® technology have reached regulatory approval.

Drug Delivery Technologies

Which dosage forms can Innocore develop?

Our technology platforms support several long-acting dosage forms, including:

  • Biodegradable microspheres
  • In situ forming depots (ISFDs)
  • Hot-melt extruded implants
  • Site-specific injectable depots
  • Customized sustained-release systems

What release durations can be achieved?

Depending on the API, indication, and administration route, sustained release periods ranging from several weeks up to 12 months can be achieved.

Which routes of administration are possible?

Our platforms support various administration routes, including:

  • Subcutaneous
  • Intramuscular
  • Intra-articular
  • Intracardiac
  • Intratumor
  • Ocular
  • Subdermal
  • Other site-specific administration routes
Peptides and Biologics

Why are peptides and biologics challenging for long-acting formulations?

Peptides and biologics are often sensitive to heat, organic solvents, pH changes, enzymatic degradation, aggregation, and chemical modification. Developing stable long-acting formulations therefore requires specialized polymer systems, analytical methods, and formulation expertise.

Does Innocore focus specifically on biologics?

Yes. Biologics and peptides represent a strategic focus area for Innocore. Our technologies have been specifically engineered to preserve biological activity and structural integrity during formulation, storage, and sustained release.

Which peptide classes are suitable?

Examples include:

  • GLP-1 receptor agonists
  • Amylin analogues
  • Peptide hormones
  • Therapeutic peptides
  • Cyclic peptides
  • Peptide conjugates
  • Dual- and multi-agonist peptides
Development Services

Which development services does Innocore provide?

We provide integrated development support, including:

  • Feasibility studies
  • Polymer selection and design
  • Formulation development
  • Process development
  • Analytical method development
  • Stability studies
  • In vitro release testing
  • Scale-up development
  • Clinical manufacturing support
  • CMC strategy support

Can Innocore support early-stage programs?

Yes. We frequently engage with clients at the discovery and preclinical stages to identify the optimal long-acting formulation strategy before significant development investments are made.

Does Innocore provide GMP manufacturing?

We support clients through process development, scale-up, technology transfer, and manufacturing strategy. For GMP manufacturing, we collaborate with a network of specialized manufacturing partners.

Partnerships

Who are Innocore's typical partners?

Our partners include:

  • Emerging biotech companies
  • Mid-sized pharmaceutical companies
  • Global pharmaceutical companies
  • Investors and strategic partners

What collaboration models does Innocore offer?

We offer flexible collaboration structures, including:

  • Fee-for-service development
  • Joint development programs
  • Strategic partnerships
  • Licensing opportunities
  • Co-development models

Can Innocore support confidential evaluation projects?

Absolutely. We regularly execute confidential feasibility and evaluation studies under appropriate confidentiality agreements.

Intellectual Property

How is intellectual property handled?

Intellectual property arrangements are tailored to each collaboration. Depending on the project structure, outcomes may include customer-owned IP, jointly developed IP, or licensing arrangements involving Innocore’s proprietary technology platforms.

Does Innocore have proprietary technology?

Yes. Innocore owns extensive intellectual property covering its SynBiosys® polymer platforms, formulations, manufacturing processes, and applications.

Getting Started

How do I determine if my API is suitable for a long-acting formulation?

The best way is to contact our business development team. Following a confidential discussion, we can typically provide an initial assessment of the feasibility, opportunities, and potential challenges for developing a long-acting injectable formulation.

How can I contact Innocore?

Please contact us through the contact form on our website or reach out directly to our team to discuss your program and objectives.